Achmea Investment Management B.V. Purchases 24,564 Shares of Gilead Sciences, Inc. $GILD

Achmea Investment Management B.V. raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 5.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 480,352 shares of the biopharmaceutical company’s stock after purchasing an additional 24,564 shares during the period. Gilead Sciences accounts for about 0.7% of Achmea Investment Management B.V.’s holdings, making the stock its 28th biggest position. Achmea Investment Management B.V.’s holdings in Gilead Sciences were worth $53,319,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in GILD. Vanguard Group Inc. raised its position in shares of Gilead Sciences by 1.6% in the second quarter. Vanguard Group Inc. now owns 119,364,226 shares of the biopharmaceutical company’s stock worth $13,233,912,000 after buying an additional 1,893,401 shares in the last quarter. Norges Bank purchased a new position in shares of Gilead Sciences during the second quarter worth approximately $2,150,268,000. Invesco Ltd. raised its position in Gilead Sciences by 12.0% in the 3rd quarter. Invesco Ltd. now owns 15,139,681 shares of the biopharmaceutical company’s stock worth $1,680,505,000 after purchasing an additional 1,618,453 shares during the period. Amundi lifted its stake in shares of Gilead Sciences by 18.2% in the 2nd quarter. Amundi now owns 10,467,411 shares of the biopharmaceutical company’s stock valued at $1,167,221,000 after acquiring an additional 1,614,355 shares during the last quarter. Finally, Legal & General Group Plc grew its holdings in Gilead Sciences by 4.2% in the 3rd quarter. Legal & General Group Plc now owns 10,210,599 shares of the biopharmaceutical company’s stock worth $1,133,376,000 after acquiring an additional 414,454 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $144.40 on Wednesday. Gilead Sciences, Inc. has a 12-month low of $93.37 and a 12-month high of $157.29. The company has a market cap of $179.26 billion, a PE ratio of 21.33, a PEG ratio of 1.90 and a beta of 0.37. The company has a current ratio of 1.55, a quick ratio of 1.40 and a debt-to-equity ratio of 0.98. The business’s fifty day simple moving average is $141.62 and its 200-day simple moving average is $127.41.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.83 by $0.03. The firm had revenue of $7.93 billion during the quarter, compared to analysts’ expectations of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The company’s revenue for the quarter was up 4.7% compared to the same quarter last year. During the same period last year, the business posted $1.90 earnings per share. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be paid a $0.82 dividend. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date of this dividend is Friday, March 13th. This represents a $3.28 dividend on an annualized basis and a yield of 2.3%. Gilead Sciences’s dividend payout ratio is 48.45%.

Analysts Set New Price Targets

Several equities analysts have commented on GILD shares. Mizuho raised their price objective on Gilead Sciences from $140.00 to $170.00 and gave the company an “outperform” rating in a research report on Wednesday, February 18th. Sanford C. Bernstein reiterated an “outperform” rating and set a $160.00 price target on shares of Gilead Sciences in a research note on Wednesday, February 11th. TD Cowen boosted their price target on Gilead Sciences from $145.00 to $160.00 and gave the stock a “buy” rating in a report on Wednesday, February 11th. Leerink Partners raised their price objective on Gilead Sciences from $146.00 to $148.00 and gave the company an “outperform” rating in a research report on Wednesday, February 11th. Finally, Royal Bank Of Canada boosted their price target on shares of Gilead Sciences from $103.00 to $118.00 and gave the stock a “sector perform” rating in a research report on Wednesday, February 11th. Twenty-four research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $157.62.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Arcellx / takeover-related coverage — reports note a Gilead-related takeover theme that drove a big one‑day move in a small biotech (Arcellx). M&A activity or strategic deals in cell therapy could be viewed positively for Gilead’s pipeline expansion and long-term growth prospects. This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal
• Neutral Sentiment: Unusual options activity flagged by market scanners — Barchart/MSN highlighted Gilead among mega‑caps with unusual options flows, which can signal speculative interest or hedging by institutions but is ambiguous for directional bias. Monitor option volumes and put/call skew for confirmation. 2 Mega-Cap Nasdaq Stocks with Unusual Options Activity: What to Watch
• Negative Sentiment: Insider sale — Johanna Mercier sold 3,000 shares at an average $144.23 on Mar 16 (disclosed to the SEC). Insider selling can be interpreted negatively by investors even if part of routine diversification or pre-set plans. Insider Sale – Johanna Mercier (SEC Filing)
• Negative Sentiment: Insider sale — CFO Andrew D. Dickinson also sold 3,000 shares at an average $144.23 on Mar 16. A sale by the CFO can draw extra attention from investors and may weigh on sentiment in the near term. Insider Sale – Andrew D. Dickinson (SEC Filing)

Insider Activity

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction on Monday, March 16th. The stock was sold at an average price of $144.23, for a total value of $432,690.00. Following the sale, the chief financial officer directly owned 179,191 shares in the company, valued at approximately $25,844,717.93. This trade represents a 1.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $144.23, for a total transaction of $432,690.00. Following the completion of the sale, the insider owned 131,779 shares in the company, valued at $19,006,485.17. The trade was a 2.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 309,280 shares of company stock worth $44,068,850. Company insiders own 0.27% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.